Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E28.66 EPS (ttm)13.85 Insider Own0.10% Shs Outstand235.23M Perf Week-1.04%
Market Cap93.38B Forward P/E20.54 EPS next Y19.33 Insider Trans-22.01% Shs Float234.98M Perf Month3.44%
Income3.28B PEG1.70 EPS next Q4.07 Inst Own92.20% Short Float1.27% Perf Quarter-3.08%
Sales10.13B P/S9.22 EPS this Y58.40% Inst Trans0.13% Short Ratio1.50 Perf Half Y29.99%
Book/sh49.65 P/B8.00 EPS next Y15.74% ROA23.30% Target Price478.76 Perf Year24.12%
Cash/sh9.15 P/C43.39 EPS next 5Y16.84% ROE30.90% 52W Range290.85 - 480.18 Perf YTD16.95%
Dividend- P/FCF28.83 EPS past 5Y29.90% ROI26.20% 52W High-17.32% Beta0.99
Dividend %- Quick Ratio2.30 Sales past 5Y17.30% Gross Margin88.10% 52W Low36.49% ATR9.55
Employees7550 Current Ratio2.70 Sales Q/Q20.00% Oper. Margin43.20% RSI (14)48.33 Volatility1.80% 2.18%
OptionableYes Debt/Eq0.05 EPS Q/Q72.80% Profit Margin32.40% Rel Volume0.66 Prev Close400.10
ShortableYes LT Debt/Eq0.05 EarningsApr 24 BMO Payout0.00% Avg Volume1.99M Price396.99
Recom2.10 SMA201.11% SMA50-3.46% SMA2009.31% Volume1,301,888 Change-0.78%
Apr-27-15Reiterated UBS Neutral $350 → $422
Apr-27-15Reiterated Argus Buy $440 → $450
Mar-23-15Downgrade Stifel Buy → Hold
Feb-02-15Reiterated Argus Buy $385 → $440
Jan-30-15Reiterated RBC Capital Mkts Outperform $400 → $445
Jan-30-15Reiterated Deutsche Bank Buy $430 → $460
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Mar-19-14Reiterated Stifel Buy $360 → $376
Mar-07-14Reiterated Barclays Overweight $325 → $352
Mar-03-14Reiterated Stifel Buy $330 → $360
Jan-30-14Reiterated UBS Neutral $300 → $310
Jan-30-14Reiterated Brean Capital Buy $293 → $377
Jan-30-14Reiterated Argus Buy $310 → $360
Jan-28-14Reiterated Deutsche Bank Buy $340 → $415
Jan-27-14Reiterated Canaccord Genuity Buy $291 → $355
Jan-16-14Reiterated Stifel Buy $296 → $321
May-29-15 03:04PM  How To Avoid Investor Traps And Invest During Turbulent Times at Forbes
11:51AM  This stock is no longer in the Top 20 most held at CNBC
May-28-15 04:01PM  Biogen 2015 Annual Shareholder Meeting Webcast Business Wire
02:59PM  Apple, SunEdison and Biogen: Hellman, Jordan Management's Top 3 Stocks Outperform the Rise in ... Gurufocus
08:25AM  Short Sellers Get Even More Ambitious Against Biotech Leaders at 24/7 Wall St.
May-27-15 07:36PM  PRIMECAP Sells Portions of Its Top Two Stakes
May-26-15 03:30PM  A Sell in May Strategy at Forbes
May-22-15 02:45PM  A Beautiful Biotech Summer? at Barrons.com
May-21-15 02:20PM  BlueBird Bio: Another Biogen Rout In The Making?
01:06PM  Jim Cramer Answers Your Twitter Questions on Tesla, Jarden, Williams-Sonoma, Wayfair at TheStreet
May-20-15 04:01PM  Biogen to Present at Bernsteins 31st Annual Strategic Decisions Conference Business Wire
May-19-15 04:44PM  3 Things Biogen's Management Wants You to Know at Investopedia
03:39PM  Value plays in health care, financials & tech
01:36PM  Good year for stock pickers: Pro
01:06PM  Healthcare Mid-Day Winners and Losers: May 19, 2015
09:39AM  Billionaire Stanley Druckenmillers Top Value Picks Include Illumina, Inc. (ILMN), Biogen Inc (BIIB), LyondellBasell Industries NV (LYB) at Insider Monkey
08:33AM  3 Best Biotech Stocks to Add to Your Portfolio at TheStreet
May-18-15 08:03AM  Is the Stock Market Due for a Correction?
May-15-15 08:37AM  The Morning Download: Hardware Advances Bring Deep Learning, Real-Time Analytics Closer to Enterprise at The Wall Street Journal
May-14-15 06:11PM  Fidelity Adds to Biogen, Amazon and Sells Microsoft, Amex at Bloomberg
04:42PM  Buy Microsoft, Biogen for Performance, Avoid Consumer Discretionary Stocks at TheStreet
12:31PM  Biogen Promotes Former Dell Exec as CIO to 'Drive Innovation' at The Wall Street Journal
May-13-15 04:01PM  Biogen to Present at the 2015 UBS Global Healthcare Conference Business Wire
09:40AM  3 Biotech Stocks See Growing Short Interest
07:30AM  Biogen Names Matt Griffiths as Chief Information Officer Business Wire
May-12-15 08:05AM  Short Sellers Start to Get Nervous on Biotech at 24/7 Wall St.
May-11-15 09:59PM  Is This Biogen's Next Billion-Dollar Blockbuster? at Investopedia
May-08-15 11:41AM  Biogen Announces Massive $5 Billion Stock Repurchase Program: Share Value To Go Up
07:47AM  Early movers: AOL, WHR, PM, CBS, NOK & more at CNBC
May-07-15 06:28PM  Biogen says it will buy back up to $5B in stock
05:46PM  Biogen shares rise after announcement of $5 billion buyback plan at MarketWatch
05:38PM  Biogen Announces $5 Billion Share Repurchase Program at noodls
05:15PM  Biogen Announces $5 Billion Share Repurchase Program Business Wire
04:01PM  Biogen to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Business Wire
12:49PM  Biogen Inc. (Nasdaq: BIIB) to Ring The Nasdaq Stock Market Opening Bell at noodls
10:00AM  Biogen Inc. (Nasdaq: BIIB) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
May-06-15 03:33PM  Cablevision Eyes Consolidation, Biotech Seen Nearing Bubble at TheStreet
10:28AM  Isis Pharmaceuticals' Q1 Loss Narrower than Expected - Analyst Blog
09:15AM  Credit Suisse Adds New Stocks to Buy to Top Picks List at 24/7 Wall St.
06:43AM  Isis Pharmaceuticals (ISIS) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
02:19AM  Acquisition target Sobi posts Q1 profit far above forecast
May-05-15 02:25PM  Zoetis Beats on Q1 Earnings, Revenue Guidance Lowered - Analyst Blog
12:45PM  Winners and Losers: Healthcare May 01, 2015
10:30AM  Pfizer, other drug giants to drive biotech
10:26AM  Young Investors: Should You Care About Dividends? at Investopedia
09:48AM  Beyond Pharma: 3 Healthcare Choices - Analyst Blog
May-04-15 04:20PM  Will Isis Pharmaceuticals (ISIS) Disappoint in Q1 Earnings? - Analyst Blog
03:34PM  Gilead Sciences Earnings Analysis: By the Numbers
12:40PM  Integra LifeSciences Tops Q1 Earnings, Revenues; View Up - Analyst Blog
10:22AM  No, the Biotech Boom Isn't Over at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Biogen, Actelion and Horizon Pharma - Press Releases
09:30AM  Acorda Posts 1Q Loss, Ampyra Generic Challenges in Focus - Analyst Blog
06:00AM  Gileads Gaffe Leads Drugmakers to Pledge More Openness on Price at Bloomberg
06:00AM  Gilead's Gaffe Leads Drugmakers to Pledge More Openness on Price
May-01-15 05:02PM  Vanguard Healthcare Fund Adds Four New Positions
04:25PM  U.S. equities recovered some of its prior day losses...
11:49AM  A Biotech Bottom? at Barrons.com
Apr-30-15 11:29PM  Alexion Pharmaceuticals (ALXN) Earnings Analysis: By the Numbers
04:59PM  Pisani: Stay calm, despite poor end to the month at CNBC
04:52PM  Biogen's Tecfidera Loses Some Luster at Investopedia
04:16PM  Top-Rated Biotech Unravels Base-Building Effort
01:04PM  BIOGEN INC. Financials
12:11PM  Biotech's boom fuels real estate here at CNBC
11:22AM  No Pain, No Gain
09:36AM  Synageva Q1 Loss Narrower-than-Expected, Pipeline in Focus - Analyst Blog
Apr-29-15 04:32PM  BioMarin Upgraded to Strong Buy, Is It in Your Portfolio? - Analyst Blog
02:37PM  Celldex 1Q Loss Narrower-Than-Expected, Pipeline in Focus - Analyst Blog
01:51PM  A Big Test for a big Biotech ETF
01:22PM  Indexes Lower, Near Session Lows As Fed Announcement Nears at Investor's Business Daily
12:08PM  [Podcast] Biogen is closing in on the holy grail for biotech stocks
09:30AM  The Zacks Analyst Blog Highlights: Celladon, Amgen, Biogen and Alnylam Pharmaceuticals - Press Releases
08:11AM  FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS at noodls
08:04AM  Biotech Stock Roundup: Weakness in Biotech Sector on Amgen & Celladon News - Analyst Blog
07:30AM  FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS Business Wire
04:06AM  As US Economy Expands, Innovation Is Tide That Lifts All Boats
Apr-28-15 04:29PM  Biogen takes on Alzheimer's
04:08PM  Biogen to Present at the 40th Annual Deutsche Bank Health Care Conference Business Wire
03:20PM  Will Teva's (TEVA) Earnings Streak Continue in Q1? - Analyst Blog
01:33PM  5 Biotech Stocks to Avoid After Monday's Slump - Analyst Blog
11:30AM  Merck (MRK) Beats on Q1 Earnings & Revenues, Ups View - Analyst Blog
11:23AM  3 Biotech Stocks Still Attractive After Monday's Sell-Off - Analyst Blog
10:43AM  Bristol-Myers Q1 Earnings Beat Driven by Strong Sales - Analyst Blog
09:50AM  No Bounce for Biotech at Barrons.com
09:40AM  Pfizer Beats on Q1 Earnings, Cuts View on Currency Woes - Analyst Blog
08:38AM  Atara Biotherapeutics (ATRA) Falls: Stock Goes Down 19.4% - Tale of the Tape
Apr-27-15 05:27PM  Anticlimactic: Stocks Sink After Record Breaking Week at Barrons.com
05:15PM  Biogen to Spend $2.5 Billion Before Alzheimers Drug Results at Bloomberg
04:30PM  Biotechs stick it to stocks at CNBC
04:01PM  Biotech drop cause for concern?
03:32PM  What's wrong with healthcare and biotech at CNBC
03:07PM  There Go the Biotechs at Barrons.com
02:26PM  Biogen Continues To Decline After Friday's Rout
10:10AM  Company News for April 27, 2015 - Corporate Summary
09:30AM  The Zacks Analyst Blog Highlights: Biogen, NV5 Holdings, Tractor Supply, ULTA Salon, Cosmetics & Fragrance and Intuit - Press Releases
08:57AM  ABWUPDATE 2-Rare diseases drugmaker Sobi jumps on takeover bid Reuters
08:30AM  Short Sellers Become More Wary of Big Biotech at 24/7 Wall St.
03:07AM  Sweden's Sobi confirms in preliminary talks on bid for company
Apr-26-15 08:25PM  Pharmaceutical company Sobi said to be open to sale -Bloomberg
08:14PM  10-Q for Biogen Idec, Inc. at Company Spotlight
08:01PM  [$$] Safety Worries Damp Sales of Biogens MS Drug Tecfidera at The Wall Street Journal
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company's products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer's disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise386.22347134,0181,874May 05 04:36 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale377.521,362514,18242,452May 05 04:34 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,134Apr 03 04:24 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale423.201,362576,39843,814Apr 02 04:29 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 27Sale430.12430184,9528,574Mar 30 04:13 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Option Exercise65.855,066333,57137,577Mar 26 04:31 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Sale449.0612,0105,393,21125,567Mar 26 04:31 PM
Rowinsky Eric KDirectorMar 20Option Exercise59.8211,667697,92022,977Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 20Sale475.0011,6675,541,82511,310Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 19Option Exercise59.822,333139,56013,643Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 19Sale436.142,3331,017,50811,310Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 17Option Exercise59.824,667279,18015,977Mar 18 05:03 PM
Rowinsky Eric KDirectorMar 17Sale425.454,6671,985,58911,310Mar 18 05:03 PM
DiPietro KennethEVP Human ResourcesMar 16Sale415.46803333,6140Mar 17 08:10 PM
SCANGOS GEORGE AChief Executive OfficerMar 13Sale412.69537221,61345,176Mar 16 08:39 PM
PANGIA ROBERT WDirectorMar 10Option Exercise47.713,625172,95417,998Mar 11 04:13 PM
SHERWIN STEPHEN ADirectorMar 10Option Exercise59.826,000358,92010,150Mar 11 04:17 PM
SHERWIN STEPHEN ADirectorMar 10Sale409.676,0002,458,0204,150Mar 11 04:17 PM
PANGIA ROBERT WDirectorMar 10Sale413.403,6251,498,57814,873Mar 11 04:13 PM
Rowinsky Eric KDirectorMar 09Option Exercise59.824,666279,12015,976Mar 11 04:15 PM
Rowinsky Eric KDirectorMar 09Sale417.234,6661,946,79511,310Mar 11 04:15 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 02Sale409.493,1741,299,7159,004Mar 03 04:44 PM
SCANGOS GEORGE AChief Executive OfficerMar 02Sale410.67825338,80345,713Mar 03 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 19Sale401.04537215,35846,538Feb 20 04:28 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale389.11825321,01647,075Feb 18 04:45 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 17Sale389.112,128828,0264,321Feb 18 04:41 PM
DiPietro KennethEVP Human ResourcesFeb 17Sale389.111,188462,263803Feb 18 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 17Sale389.11418162,64815,004Feb 18 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.0015,599045,547Feb 17 09:32 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.0047101,450Feb 17 09:16 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.003,63407,152Feb 17 08:54 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,20101,318Feb 17 08:50 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.001,605015,805Feb 17 08:47 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.004,299022,960Feb 17 08:44 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,738033,214Feb 17 08:40 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.005,200016,481Feb 17 08:37 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.003,769028,634Feb 17 08:34 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,76402,706Feb 17 08:30 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.003,60108,771Feb 17 08:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833043,148Feb 11 04:25 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 10Sale398.111,143455,03914,574Feb 11 04:26 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691022,194Feb 10 05:06 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691032,744Feb 10 05:07 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82407,088Feb 10 05:08 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270029,255Feb 11 04:25 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909027,716Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,398Feb 10 05:11 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Sale398.05856340,73114,574Feb 10 05:11 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468014,542Feb 10 05:14 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277015,851Feb 10 05:11 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70505,802Feb 10 05:10 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498024,625Feb 10 05:12 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,63606,147Feb 10 05:08 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023029,590Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191018,646Feb 10 05:06 PM
DiPietro KennethEVP Human ResourcesFeb 02Sale389.031,656644,2340Feb 03 06:35 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 02 07:46 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,157013,133Feb 02 07:43 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,15705,157Feb 02 07:40 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM